ABBOTT LABORATORIES Share-based Payment Arrangement, Expense, Tax Benefit
ABBOTT LABORATORIES (ABT) reported Share-based Payment Arrangement, Expense, Tax Benefit of $223.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-20.
Financial Statements › Expense Statement › Income Tax
us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense · last filed 2026-02-20
- ABBOTT LABORATORIES share-based payment arrangement, expense, tax benefit for the quarter ending 2020-12-31 was $113.00M, a 10.78% increase year-over-year.
- ABBOTT LABORATORIES share-based payment arrangement, expense, tax benefit for the quarter ending 2020-09-30 was $20.00M, a 300.00% increase year-over-year.
- ABBOTT LABORATORIES share-based payment arrangement, expense, tax benefit for the quarter ending 2020-06-30 was $20.00M, a 20.00% decline year-over-year.
- ABBOTT LABORATORIES share-based payment arrangement, expense, tax benefit for the quarter ending 2020-03-31 was $47.00M, a 27.69% decline year-over-year.
- ABBOTT LABORATORIES share-based payment arrangement, expense, tax benefit for fiscal 2025 was $223.00M, a 23.20% increase from fiscal 2024.
- ABBOTT LABORATORIES share-based payment arrangement, expense, tax benefit for fiscal 2024 was $181.00M, a 25.69% increase from fiscal 2023.
- ABBOTT LABORATORIES share-based payment arrangement, expense, tax benefit for fiscal 2023 was $144.00M, a 15.29% decline from fiscal 2022.
- ABBOTT LABORATORIES share-based payment arrangement, expense, tax benefit for fiscal 2022 was $170.00M, a 36.33% decline from fiscal 2021.
| Period end | Share-based Payment Arrangement, Expense, Tax Benefit 3 month | Share-based Payment Arrangement, Expense, Tax Benefit 6 month | Share-based Payment Arrangement, Expense, Tax Benefit 9 month | Share-based Payment Arrangement, Expense, Tax Benefit 12 month |
|---|---|---|---|---|
| 2025-12-31 | $223.00M 10-K · filed 2026-02-20 | |||
| 2024-12-31 | $181.00M 10-K · filed 2026-02-20 | |||
| 2023-12-31 | $144.00M 10-K · filed 2026-02-20 | |||
| 2022-12-31 | $170.00M 10-K · filed 2025-02-21 | |||
| 2021-12-31 | $267.00M 10-K · filed 2024-02-16 | |||
| 2020-12-31 | $113.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-17 | $133.00M derived: sum of 2 quarters · filed 2023-02-17 | $153.00M derived: sum of 3 quarters · filed 2023-02-17 | $200.00M 10-K · filed 2023-02-17 |
| 2020-09-30 | $20.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | $40.00M derived: sum of 2 quarters · filed 2020-11-04 | $87.00M 10-Q · filed 2020-11-04 | $189.00M derived: sum of 4 quarters · filed 2022-02-18 |
| 2020-06-30 | $20.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-29 | $67.00M 10-Q · filed 2020-07-29 | $169.00M derived: sum of 3 quarters · filed 2022-02-18 | $174.00M derived: sum of 4 quarters · filed 2022-02-18 |
| 2020-03-31 | $47.00M 10-Q · filed 2020-04-29 | $149.00M derived: sum of 2 quarters · filed 2022-02-18 | $154.00M derived: sum of 3 quarters · filed 2022-02-18 | $179.00M derived: sum of 4 quarters · filed 2022-02-18 |
| 2019-12-31 | $102.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-18 | $107.00M derived: sum of 2 quarters · filed 2022-02-18 | $132.00M derived: sum of 3 quarters · filed 2022-02-18 | $197.00M 10-K · filed 2022-02-18 |
| 2019-09-30 | $5.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | $30.00M derived: sum of 2 quarters · filed 2020-11-04 | $95.00M 10-Q · filed 2020-11-04 | $200.00M derived: sum of 4 quarters · filed 2021-02-19 |
| 2019-06-30 | $25.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-29 | $90.00M 10-Q · filed 2020-07-29 | $195.00M derived: sum of 3 quarters · filed 2021-02-19 | $204.00M derived: sum of 4 quarters · filed 2021-02-19 |
| 2019-03-31 | $65.00M 10-Q · filed 2020-04-29 | $170.00M derived: sum of 2 quarters · filed 2021-02-19 | $179.00M derived: sum of 3 quarters · filed 2021-02-19 | $185.00M derived: sum of 4 quarters · filed 2021-02-19 |
| 2018-12-31 | $105.00M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-19 | $114.00M derived: sum of 2 quarters · filed 2021-02-19 | $120.00M derived: sum of 3 quarters · filed 2021-02-19 | $185.00M 10-K · filed 2021-02-19 |
| 2018-09-30 | $9.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-31 | $15.00M derived: sum of 2 quarters · filed 2019-10-31 | $80.00M 10-Q · filed 2019-10-31 | |
| 2018-06-30 | $6.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-31 | $71.00M 10-Q · filed 2019-07-31 | ||
| 2018-03-31 | $65.00M 10-Q · filed 2019-05-01 | |||
| 2012-12-31 | $132.00M 10-K · filed 2013-02-15 | |||
| 2011-12-31 | $116.00M 10-K · filed 2013-02-15 | |||
| 2010-12-31 | $119.00M 10-K · filed 2013-02-15 | |||
| 2009-12-31 | $118.00M 10-K · filed 2012-02-21 | |||
| 2008-12-31 | $117.00M 10-K · filed 2011-02-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |